Why Do We Age? The Science of Aging Explained

Every cell in your body is executing the same molecular machinery your ancestors used 500 million years ago. The instructions for building proteins, replicating DNA, and disposing of cellular debris have remained essentially unchanged. Yet the body that runs this ancient software deteriorates predictably over time — hair grays, muscles thin, arteries stiffen, and neurons die — following a trajectory so consistent that gerontologists can plot it on actuarial tables. The question of why this happens — not philosophically, but mechanistically — has occupied biologists for over a century. In the last two decades, the field has converged on a framework that is both more complicated and more tractable than anyone expected.

Aging Is Not One Thing

The first thing to understand is that "aging" is not a single process with a single cause. It is a cluster of interconnected molecular failures that accumulate because natural selection has no strong pressure to fix problems that emerge after an organism's reproductive years. Evolution, bluntly, does not care what happens to you at 70.

This view — formalized in the disposable soma theory by evolutionary biologist Tom Kirkwood — holds that organisms evolved to allocate finite metabolic resources between reproduction (which passes genes on) and somatic maintenance (which protects the body that carries those genes). Past reproductive age, maintenance becomes less evolutionarily "worthwhile," so repair mechanisms that are imperfect in youth become progressively more inadequate with time. The body is not designed to last; it is designed to reproduce, and longevity is a byproduct of how much repair was worth the evolutionary investment.

Source: Kirkwood, T.B.L., Nature (1977) — Original formulation of the disposable soma theory, establishing the evolutionary logic of senescence.

The mechanistic picture was formalized in a landmark 2013 review in Cell by López-Otín and colleagues, which identified nine molecular hallmarks of aging in mammals. A 2023 update expanded the list to twelve. Each hallmark is a distinct class of cellular malfunction that satisfies three criteria: it appears during normal aging, experimentally accelerating it speeds aging, and attenuating it extends healthy lifespan (in model organisms).

Source: López-Otín, C. et al., Cell (2013) — "The Hallmarks of Aging" — original nine-hallmark framework. Expanded to twelve hallmarks: López-Otín, C. et al., Cell (2023).

The Twelve Hallmarks of Aging

Hallmark	What goes wrong
Genomic instability	DNA damage accumulates faster than repair mechanisms fix it
Telomere attrition	Chromosome caps shorten with each cell division
Epigenetic alterations	Gene expression patterns drift from youthful baselines
Loss of proteostasis	Misfolded and damaged proteins accumulate
Disabled macroautophagy	Cellular self-cleaning machinery declines
Deregulated nutrient sensing	Insulin/IGF-1, mTOR, AMPK, and sirtuins fall out of balance
Mitochondrial dysfunction	Energy production declines, reactive oxygen species increase
Cellular senescence	Damaged cells stop dividing but stay alive, secreting inflammatory signals
Stem cell exhaustion	Tissue repair capacity diminishes
Altered intercellular communication	Chronic low-grade inflammation rises (inflammaging)
Dysbiosis	Gut microbiome composition shifts adversely
Compromised autophagy	(Merged into macroautophagy in revised framework)

These hallmarks do not operate independently. They are better understood as a feedback network: genomic instability triggers cellular senescence, which drives altered intercellular communication (inflammation), which further damages mitochondria, which generate more reactive oxygen species, which cause more genomic damage. Understanding any one of them requires understanding how it talks to the others.

Telomeres: The Replication Clock

Telomere — a repetitive DNA sequence (TTAGGG in humans, repeated thousands of times) that caps the ends of each chromosome like the plastic tip on a shoelace. Telomeres protect chromosome ends from being recognized as DNA damage and from fusing with other chromosomes.

The problem is replication geometry. When DNA polymerase copies a chromosome, it cannot complete the very end of the strand — the so-called "end-replication problem." With each cell division, a telomere loses roughly 50–200 base pairs. After enough divisions, telomeres become critically short. The cell interprets this as DNA damage, and a damage-response program activates: the cell either undergoes apoptosis (programmed death) or enters senescence.

In germline cells (sperm, eggs) and most cancer cells, an enzyme called telomerase adds telomeric repeats back onto chromosome ends, maintaining their length. In most somatic (body) cells, telomerase expression is very low or absent. This means somatic cells have a finite replicative lifespan — a limit independently discovered by Leonard Hayflick in 1961 and now called the Hayflick limit (roughly 50 divisions for human fibroblasts).

Telomere length in white blood cells is routinely used as a biomarker for biological aging. Shorter average telomere length correlates with higher all-cause mortality, even after controlling for chronological age. But the relationship is complex: telomere length reflects both the rate of cell turnover and exposure to oxidative stress, which also degrades telomeres chemically.

Source: Blackburn, E.H., Epel, E.S., & Lin, J., Science (2015) — Review of telomere biology, stress-accelerated telomere shortening, and implications for disease. (Blackburn shared the 2009 Nobel Prize in Physiology or Medicine for telomerase discovery.)

Cellular Senescence: Cells That Refuse to Die

When a cell's telomeres shorten critically, or when it sustains severe DNA damage or oncogene activation, it can enter a state called senescence — a permanent cell-cycle arrest from which it cannot exit. Senescent cells stop dividing, which is protective against cancer (a cell that cannot divide cannot form a tumor). But they do not die; they persist in tissue and release a cocktail of inflammatory cytokines, proteases, and growth factors called the senescence-associated secretory phenotype (SASP).

In youth, the immune system clears senescent cells efficiently. With age, both the accumulation rate of senescent cells rises and the immune system's clearance capacity falls, so senescent cells build up. The SASP they secrete causes chronic low-grade inflammation, degrades the extracellular matrix, impairs neighboring stem cells, and can even trigger senescence in adjacent healthy cells — a phenomenon called paracrine senescence. Think of a single rotten fruit in a bowl that accelerates the spoiling of the others.

The causal role of senescent cell accumulation in aging has been demonstrated cleanly in genetically modified mice (the "INK-ATTAC" model) in which senescent cells can be selectively eliminated by a drug. Clearing these cells in old mice improved physical function, reduced cataracts, and extended median lifespan by 17–35%.

Source: Baker, D.J. et al., Nature (2016) — Clearance of p16Ink4a-positive senescent cells delays age-associated disorders and extends healthy lifespan in mice.

Epigenetic Drift: The Aging Clock in the DNA

Epigenetics refers to heritable changes in gene expression that do not involve changes to the DNA sequence itself. The two most studied epigenetic mechanisms are DNA methylation (addition of methyl groups to cytosine bases, typically silencing genes) and histone modification (chemical tags on the proteins around which DNA is wrapped, which control gene accessibility).

During development, epigenetic patterns are carefully established to define cell identity and regulate gene expression appropriately for each tissue. With age, these patterns drift: some genes that should be silenced become active; some that should be active are silenced. This epigenetic reprogramming is sufficiently systematic that analyzing DNA methylation patterns at specific genomic sites allows researchers to calculate a person's epigenetic age (or "biological age") independently of their chronological age — a tool called the Horvath clock after its developer.

Epigenetic clocks have revealed that biological age can diverge substantially from chronological age based on lifestyle, stress, disease, and environment. Obese individuals and smokers show accelerated epigenetic aging; caloric restriction and high aerobic fitness correlate with slower epigenetic aging. This is not merely a statistical curiosity: epigenetic age is a better predictor of mortality risk than chronological age in several large cohort studies.

Source: Horvath, S., Genome Biology (2013) — Development of the epigenetic clock using DNA methylation data across multiple tissues to measure biological aging.

Mitochondrial Dysfunction and the Free Radical Theory

Mitochondria — the organelles that produce ATP (adenosine triphosphate, the cell's energy currency) via oxidative phosphorylation. As a byproduct of this process, electrons occasionally escape the electron transport chain and react with oxygen to form reactive oxygen species (ROS) — molecules like superoxide (O₂⁻), hydrogen peroxide (H₂O₂), and the hydroxyl radical (•OH).

The free radical theory of aging (proposed by Denham Harman in 1956) holds that cumulative ROS damage to DNA, proteins, and lipids drives aging. This remains partly true: ROS do cause oxidative damage that accumulates with age. But the story is more complicated than Harman envisioned. Antioxidant supplementation does not reliably extend lifespan in humans and in some studies shows adverse effects. Paradoxically, low-level ROS signaling appears to be necessary for activating stress-response pathways that are beneficial (a phenomenon called hormesis).

The current view is that mitochondrial dysfunction contributes to aging primarily through declining ATP production (limiting energy for cellular maintenance), through mitochondria-derived ROS damaging mitochondrial DNA (mtDNA, which is especially vulnerable because it lacks the protective histones of nuclear DNA), and through triggering inflammatory signaling as damaged mitochondria leak their contents. Mitochondrial DNA mutations accumulate with age and are linked to age-related muscle loss (sarcopenia), cognitive decline, and cardiovascular dysfunction.

Source: Bratic, A. & Larsson, N.G., Journal of Clinical Investigation (2013) — Mitochondrial DNA mutations, aging, and the role of mitochondrial biogenesis in lifespan.

Nutrient Sensing Pathways: mTOR, AMPK, and the Longevity Connection

Some of the most robust interventions known to extend lifespan in model organisms target nutrient-sensing pathways. These pathways evolved to coordinate cellular growth and metabolism with food availability. When chronically over-activated (as tends to happen in calorie-dense modern environments), they appear to accelerate several aging hallmarks.

mTOR (mechanistic target of rapamycin) — a kinase that stimulates protein synthesis and cell growth when nutrients are plentiful. When inhibited (by caloric restriction or by the drug rapamycin), cells shift from growth mode to repair mode: autophagy (cellular self-cleaning) increases, senescence is partially suppressed. Rapamycin extends median lifespan in mice by 9–14% when started in late middle age — a remarkable finding given it was administered to already-aged animals.

AMPK (AMP-activated protein kinase) — activated when cellular energy is low, it inhibits mTOR and stimulates mitochondrial biogenesis and autophagy. Exercise activates AMPK, which partially explains why physical activity has such broad anti-aging effects at the cellular level.

Sirtuins — a family of NAD⁺-dependent deacetylases that regulate DNA repair, mitochondrial function, and stress responses. Their activity declines with age in part because NAD⁺ levels fall with age. This has driven interest in NAD⁺ precursor supplementation (NMN, NR) as potential longevity interventions, though human trial data remain limited and mixed.

Source: Kennedy, B.K. & Lamming, D.W., Cell Metabolism (2016) — mTOR signaling in aging and age-related disease, rapamycin effects in model organisms.

The Inflammation Connection: Inflammaging

One of the most consistent features of the aging body is elevated levels of circulating pro-inflammatory molecules — interleukin-6, TNF-α, CRP — even in the absence of active infection or injury. This state of chronic, sterile, low-grade inflammation has been termed inflammaging (a portmanteau of inflammation and aging coined by Claudio Franceschi).

Inflammaging arises from multiple sources: SASP from senescent cells, leakage of damaged mitochondria, degradation of the gut barrier (allowing bacterial products to enter circulation; see how digestion works), and declining regulatory T-cell function. It is not merely a marker of aging but a driver: inflammatory cytokines accelerate muscle loss, promote insulin resistance, contribute to neurodegeneration, and impair stem cell function.

This is why several age-related conditions — cardiovascular disease, type 2 diabetes, Alzheimer's disease, osteoporosis — share inflammation as a common mechanism even though their primary pathologies appear distinct.

Source: Franceschi, C. et al., Nature Reviews Immunology (2018) — "Inflammaging" as a driver of multiple age-related diseases and its relationship to immunosenescence.

Current Longevity Research: What Is Actually Being Tested

Several interventions that reliably extend lifespan in model organisms are now in early or mid-stage human trials.

Senolytics — drugs that selectively clear senescent cells. The combination of dasatinib (a leukemia drug) and quercetin (a plant flavonoid) cleared senescent cells in early human trials, improving physical function in patients with idiopathic pulmonary fibrosis and diabetic kidney disease. Larger trials are ongoing.

Rapamycin and mTOR inhibitors — short-term pulsed rapamycin improved vaccine response (an immune aging marker) in elderly humans in a small Novartis-funded trial. Multiple trials of rapalogs (rapamycin analogs) in healthy older adults are ongoing.

Caloric restriction mimetics — metformin (a diabetes drug that activates AMPK) is being tested in the TAME trial (Targeting Aging with Metformin), the first FDA-approved trial specifically designed to test an anti-aging intervention.

Partial reprogramming — introducing Yamanaka factors (transcription factors that can reprogram adult cells to pluripotency) transiently to rejuvenate epigenetic patterns without full dedifferentiation. Several biotech companies are pursuing this; results in mice have been striking but the translation to humans remains early.

None of these interventions has yet been shown to extend human lifespan in a controlled trial. The challenge is measuring aging outcomes: a trial designed to detect a 5-year increase in median lifespan would take decades. Researchers are working to validate shorter-term biomarkers (epigenetic clocks, proteomics, metabolomics) as surrogate endpoints.

Source: Barzilai, N. et al., Cell Metabolism (2016) — Design and rationale for the TAME trial targeting aging with metformin.

Why Some People Age Slower

Population studies of centenarians reveal that exceptional longevity clusters in families, suggesting substantial genetic contribution. Genome-wide association studies have identified variants in the APOE, FOXO3, and CETP genes as consistently associated with extreme longevity across multiple populations. But genetics explains only about 25–30% of variance in lifespan; environment and behavior account for the rest.

The clearest lifestyle correlates of slower biological aging (as measured by epigenetic clocks and other biomarkers):

• High aerobic fitness (activates AMPK, mitophagy, reduces inflammaging)
• Absence of smoking (accelerates telomere shortening and epigenetic aging by roughly 5 years)
• Healthy sleep (sleep is when the brain clears amyloid and other cellular debris; the brain's own maintenance relies on deep sleep)
• Social connection (chronic loneliness correlates with accelerated inflammaging, independent of other lifestyle factors)
• Caloric moderation without malnutrition (caloric restriction in rhesus macaques in a 20-year NIA study reduced age-related disease incidence significantly)

Source: Deelen, J. et al., Nature Communications (2019) — Genome-wide association meta-analysis of longevity in over 300,000 individuals identifying key genetic loci.

Frequently Asked Questions

Q: Is aging a disease?
A: Biologically, aging fits the definition of a pathological process — it is progressive, causes functional decline, and increases mortality risk. The WHO's ICD-11 (International Classification of Diseases, 11th revision) added "old age" as a classifiable condition, though it does not call aging itself a disease. Practically, the disease-vs-process distinction matters because the FDA has historically required a specific disease endpoint in clinical trials, which is why the TAME trial is specifically designed to test against age-related diseases as a composite outcome rather than aging per se.

Q: Do telomeres actually control how long you live?
A: Telomere length is a contributor to aging, not the controlling variable. Mice engineered with very long telomeres live longer; mice with very short ones age prematurely. But in humans, telomere length accounts for only a small fraction of lifespan variance. Many people with below-average telomere length live long healthy lives; the relationship between telomere length and aging operates through probability, not destiny.

Q: Does caloric restriction extend human lifespan?
A: In virtually every organism tested — yeast, worms, flies, mice, rats, and rhesus monkeys — caloric restriction (typically 20–40% below ad libitum intake without malnutrition) extends both median and maximum lifespan. The CALERIE trial in humans showed that 25% caloric restriction for two years improved several aging biomarkers. Whether it extends human lifespan is unknown; the trial was not long enough to test that.

Q: Why do women live longer than men on average?
A: The female longevity advantage (roughly 4–6 years in high-income countries) has multiple proposed explanations: estrogen's anti-inflammatory and antioxidant effects, lower cardiovascular disease rates before menopause, behavioral differences in health-seeking and risk-taking, and having two X chromosomes (so a damaged copy of an X-linked gene can be backed up by the second copy). No single factor is decisive; the gap appears to have both biological and social-behavioral components.

Q: Can NAD+ supplements reverse aging?
A: NAD⁺ levels fall with age and restoring them in old mice (via NMN or NR supplementation) improves mitochondrial function, muscle endurance, and cognitive measures in some studies. Human trials show that NMN and NR do raise blood NAD⁺ levels. Whether this translates into measurable anti-aging effects in humans is not yet established. The research is promising but not conclusive as of 2026.

Q: What is the maximum human lifespan?
A: The oldest reliably verified human age at death is 122 years and 164 days, achieved by Jeanne Calment of France, who died in 1997. Demographic analyses suggest a biological limit exists somewhere between 115 and 150 years for humans, based on the rate at which the oldest-age records have expanded over time. Some researchers (notably Jan Vijg) argue that maximum lifespan has already plateaued; others disagree and believe interventions targeting aging hallmarks could push it further.

Source: Dong, X., Milholland, B., & Vijg, J., Nature (2016) — Evidence for an upper limit to human lifespan based on maximum reported age at death data.

The Takeaway

Aging is not a single thing winding down — it is a dozen interacting molecular failure modes that compound each other over decades. Telomere shortening, cellular senescence, epigenetic drift, mitochondrial decline, and chronic inflammation each drive the others, forming a feedback network more complex than any single intervention can address. The field's progress in the last decade has been extraordinary: we can now measure biological age more precisely than ever, we understand the mechanisms well enough to target them in animal models, and the first generation of human trials testing genuine anti-aging interventions is underway. Whether the next decade delivers clinically significant extensions of healthy human lifespan remains genuinely uncertain — but for the first time, the question is one of biology and trial design rather than wishful thinking.

---

Read next:

• How the Brain Works Explained
• How the Immune System Works
• How Muscles Work Explained